Sonic Healthcare (ASX:SHL): FY26 Pathology Revenue, Earnings and Cash Flow

Aditi Sarkar

12 November 2026 04:39 PM AEDT

Sonic Healthcare (ASX:SHL): FY26 Pathology Revenue, Earnings and Cash Flow

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Sonic Healthcare (ASX:SHL) reported AUD 10.867 billion FY26 revenue.
Underlying EBITDA increased 11% to AUD 1.933 billion.
Underlying net profit rose 17% to AUD 621 million.
SHL traded at AUD 19.855 on 12 November 2026, up 0.13%.

Sonic Healthcare Limited (ASX:SHL) provides pathology, clinical laboratory and radiology services to doctors, hospitals and patients across Australia and overseas markets. Its stock changed hands at AUD 19.855 on 12 November 2026, up 0.13% during the session. The company’s August 2026 annual results highlighted higher Revenue and underlying earnings, cash generation and continued Investment in diagnostic capacity.

Global Diagnostic Services

Sonic Healthcare (ASX:SHL) operates clinical laboratories in Australia, Europe, New Zealand and North America alongside radiology and medical-centre activities. Pathology services include processing clinical specimens and reporting laboratory findings to referring clinicians. Radiology services involve diagnostic imaging. The group also operates Australian medical centres and occupational health services. This operating mix provides exposure to local healthcare funding systems, labour markets and reimbursement structures, all of which affect the conversion of testing Demand into revenue and operating profit.

FY26 Financial Performance

For the year ended 30 June 2026, Sonic Healthcare (ASX:SHL) reported revenue of AUD 10.867 billion, up 13%. Underlying Earnings before interest, tax, Depreciation and Amortisation (EBITDA) increased 11% to AUD 1.933 billion. Statutory EBITDA was AUD 1.882 billion, up 9%. Underlying net profit increased 17% to AUD 621 million, compared with statutory net profit of AUD 608 million, up 18%. Underlying Earnings Per Share increased 14% to 125.6 Australian cents, while statutory earnings per share reached 123.0 cents. These distinctions between adjusted and statutory figures are important when comparing operating performance.

The company separately reported organic revenue growth of 5% and an 8% increase in cash generated from operations to AUD 1.41 billion. Total revenue growth therefore reflects more than organic demand alone. Reported underlying EBITDA growth was below the percentage increase in revenue, indicating that costs and acquired-business contributions also need consideration. Company disclosures identify Acquisition synergies, Operating Leverage and cost management as factors in the result.

Laboratory Investment and Business Mix

Sonic Healthcare (ASX:SHL) has continued investment in laboratories and associated infrastructure. In June 2026, the group announced a AUD 445 million sale-and-leaseback transaction involving a life sciences Facility with Charter Hall under a 20-year Lease structure. A sale-and-leaseback can change the ownership and rental profile of a property without transferring the underlying diagnostic business. The reported transaction value should not be confused with recurring laboratory revenue or operating earnings. Financial reporting remains the appropriate reference for the transaction’s accounting effect.

Risks and Sector Considerations

Diagnostic services businesses are exposed to healthcare funding decisions, labour and consumable costs, technology expenditure and regulatory compliance. Clinical laboratory volumes can vary by region and test type, while acquisition integration requires operational coordination. For Sonic Healthcare (ASX:SHL), the timing of revenue, Capital commitments and lease obligations matters when evaluating earnings conversion into cash. Currency translation is also relevant because the business operates in multiple international markets. Headline growth rates alone do not establish how each region contributed.

What to Watch Next

Subsequent reporting may provide further detail on the composition of organic growth, regional margins, cost initiatives, acquisition integration and cash flow. Investors can also monitor the development of radiology and medical centre activities relative to pathology. The company’s detailed financial statements distinguish statutory and underlying profitability and disclose balance-sheet and lease obligations. Those measures offer a more complete view than revenue expansion in isolation.

Key Insights

Sonic’s FY26 results recorded growth in reported revenue, underlying EBITDA, net profit and operating cash generation. The laboratory and imaging footprint exposes the company to multiple healthcare systems, with costs, funding policies and acquisition execution affecting subsequent results. Comparison of underlying and statutory measures remains essential.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.